Ad
related to: chemours stock
Search results
Chemours (CC) Stock Sinks As Market Gains: What You Should Know
Zacks via Yahoo Finance· 2 years agoChemours (CC) closed at $31.44 in the latest trading session, marking a -0.47% move from the prior...
Chemours (CC) Stock Jumps 7.4%: Will It Continue to Soar?
Zacks via Yahoo Finance· 2 years agoChemours (CC) witnessed a jump in share price last session on above-average trading volume. The...
Is Chemours (CC) Stock Outpacing Its Basic Materials Peers This Year?
Zacks via Yahoo Finance· 2 years agoThe Basic Materials group has plenty of great stocks, but investors should always be looking for...
Here's Why You Should Hold Onto Chemours (CC) Stock for Now
Zacks via Yahoo Finance· 2 years agoWhile Chemours (CC) is exposed to supply-chain issues and higher input costs, it gains on healthy...
Why Chemours Stock Soared Today
Motley Fool via Yahoo Finance· 3 months agoShares of Chemours (NYSE: CC) rallied 16.8% today after the chemical company concluded an internal review that's loomed over the business for the past...
Chemours (CC) Lags Q3 Earnings and Revenue Estimates
Zacks via Yahoo Finance· 7 months agoChemours (CC) delivered earnings and revenue surprises of -16.88% and 3.63%, respectively, for the quarter ended September 2023. Do the numbers hold...
Chemours (CC) Stock Hits 52-Week High: What's Driving It?
Zacks via Yahoo Finance· 2 years agoShares of The Chemours Company CC scaled a fresh 52-week high of $44.95 on Jun 6, before closing the...
Chemours (CC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Zacks via Yahoo Finance· 2 years agoAfter losing some value lately, a hammer chart pattern has been formed for Chemours (CC), indicating...
Why Chemours Stock Is Plunging Today
Motley Fool via Yahoo Finance· 2 months agoChemours (NYSE: CC) surpassed top- and bottom-line quarterly expectations, but investors are more focused on the drama going on behind the scenes. Shares...
Chemours (CC) to Post Q2 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 2 years agoChemours' (CC) second-quarter performance is likely to reflect the increasing adoption of Opteon...